Association of Overlapped and Un-overlapped Comorbidities with COVID-19 Severity and Treatment Outcomes: A Retrospective Cohort Study from Nine Provinces in China
Overview
Authors
Affiliations
Objective: Several COVID-19 patients have overlapping comorbidities. The independent role of each component contributing to the risk of COVID-19 is unknown, and how some non-cardiometabolic comorbidities affect the risk of COVID-19 remains unclear.
Methods: A retrospective follow-up design was adopted. A total of 1,160 laboratory-confirmed patients were enrolled from nine provinces in China. Data on comorbidities were obtained from the patients' medical records. Multivariable logistic regression models were used to estimate the odds ratio ( ) and 95% confidence interval (95% ) of the associations between comorbidities (cardiometabolic or non-cardiometabolic diseases), clinical severity, and treatment outcomes of COVID-19.
Results: Overall, 158 (13.6%) patients were diagnosed with severe illness and 32 (2.7%) had unfavorable outcomes. Hypertension (2.87, 1.30-6.32), type 2 diabetes (T2DM) (3.57, 2.32-5.49), cardiovascular disease (CVD) (3.78, 1.81-7.89), fatty liver disease (7.53, 1.96-28.96), hyperlipidemia (2.15, 1.26-3.67), other lung diseases (6.00, 3.01-11.96), and electrolyte imbalance (10.40, 3.00-26.10) were independently linked to increased odds of being severely ill. T2DM (6.07, 2.89-12.75), CVD (8.47, 6.03-11.89), and electrolyte imbalance (19.44, 11.47-32.96) were also strong predictors of unfavorable outcomes. Women with comorbidities were more likely to have severe disease on admission (5.46, 3.25-9.19), while men with comorbidities were more likely to have unfavorable treatment outcomes (6.58, 1.46-29.64) within two weeks.
Conclusion: Besides hypertension, diabetes, and CVD, fatty liver disease, hyperlipidemia, other lung diseases, and electrolyte imbalance were independent risk factors for COVID-19 severity and poor treatment outcome. Women with comorbidities were more likely to have severe disease, while men with comorbidities were more likely to have unfavorable treatment outcomes.
Shang X, Cao Y, Guo Y, Zhang L, Li J, Zhang H Infect Dis Poverty. 2024; 13(1):97.
PMID: 39696533 PMC: 11658301. DOI: 10.1186/s40249-024-01263-8.
Zhang H, Liu Y, Shang X, Cao Y, Li J, Chen G Front Pharmacol. 2024; 15:1422773.
PMID: 39144631 PMC: 11322107. DOI: 10.3389/fphar.2024.1422773.
Jagirdhar G, Qasba R, Pattnaik H, Rama K, Banga A, Reddy S World J Gastroenterol. 2023; 29(21):3362-3378.
PMID: 37377589 PMC: 10292144. DOI: 10.3748/wjg.v29.i21.3362.
Electrolyte imbalances as poor prognostic markers in COVID-19: a systemic review and meta-analysis.
Song H, Chia A, Tan B, Teo C, Lim V, Chua H J Endocrinol Invest. 2022; 46(2):235-259.
PMID: 36070177 PMC: 9449297. DOI: 10.1007/s40618-022-01877-5.
Zong X, Liang N, Wang J, Li H, Wang D, Chen Y Front Pharmacol. 2022; 13:849598.
PMID: 35910390 PMC: 9326303. DOI: 10.3389/fphar.2022.849598.